Table 2.
Response status by subtype in evaluable patients (n = 27)
| Subtype | n | ORR | CR/CRu | PR | SD | ||||
|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | ||
| Nodal MZL* | 16 | 16 | 88 | 10 | 56 | 4 | 22 | 2 | 11 |
| Extranodal MZL/MALT lymphoma | 10 | 10 | 80 | 8 | 73 | 0 | 0 | 2 | 18 |
| Splenic MZL | 1 | 1 | 100 | 1 | 100 | 0 | 0 | 0 | 0 |
| All patients | 27 | 25 | 93 | 19 | 70 | 6 | 22 | 2 | 7 |
CR, complete response; CRu, CR unconfirmed; MALT, mucosa‐associated lymphoid tissue; MZL, marginal zone lymphoma; ORR, overall response rate; PR, partial response; SD, stable disease.
*
One patient with extranodal MZL and two patients with nodal MZL did not have a response analysis available.